Search Results

CHOICE Outcomes at 1 Year Show No Difference Between Self-Expandable and Balloon-Expandable TAVR Devices

August 14, 2015—One-year results from the CHOICE trial evaluating transcatheter aortic valve replacement (TAVR) were published by Mohamed Abdel-Wahab, MD, et al in the Journal of American College of Cardiology (JACC; 2015;66:791–800). The CHOICE trial was a randomized comparison of TAVR in high-risk patients with severe aortic stenosis using the self-expandable CoreValve (Medtronic plc) versus the balloon-expandable Sapien XT (Edwards Lifesciences).

German TAVI Registry Analysis Identifies Predictors of 1-Year Mortality

August 6, 2014—An evaluation of the predictors of 1-year mortality in patients with aortic regurgitation after transcatheter aortic valve implantation (TAVI) in the multicenter German TAVI registry was published by Mohamed Abdel-Wahab, MD, et al in Heart  (2014;100:1250-1256).

CHOICE Trial Favors Balloon-Expandable Over Self-Expanding TAVR Devices

March 30, 2014—The American College of Cardiology (ACC) announced that a first-ever randomized head-to-head comparison of two devices commonly used to treat aortic stenosis finds that balloon-expandable transcatheter valves result in more successful procedures and relieve symptoms more frequently than self-expanding valves.

Vivasure’s PerQseal Elite Vascular Closure System Receives CE Mark Approval

April 22, 2025—Vivasure Medical, an Ireland-based developer of fully absorbable technology for percutaneous vessel closure, announced European CE Mark approval of the PerQseal Elite vascular closure system.

CHOICE-CLOSURE Randomized Study Compares Plug-Based and Suture-Based Vascular Closure Devices After TAVR

November 5, 2021—The CHOICE-CLOSURE randomized trial comparing different closure device strategies after transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis but a higher rate of access-site or access-related vascular complications.